LINC02885: A Potential Drug Target and Biomarker (G101926957)

Target Name: LINC02885

NCBI ID: G101926957

LINC02885

Other Name(s): Long intergenic non-protein coding RNA 2885 | long intergenic non-protein coding RNA 2885 | ISX-AS1

LINC02885: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These small RNAs play a crucial role in gene regulation and are involved in the development and progression of various diseases, including cancer. LINC02885, a long intergenic non-protein coding RNA (lncRNA), has been identified as a potential drug target and biomarker for several diseases.

LINC02885 is a 2885-nt RNA molecule that is located between the genes HOMER-S100 and HOMER-S200 on chromosome 16. It is characterized by a unique 5'-end that is rich in uracils and guanines, as well as a unique 3'-end that is rich in adenylates. LINC02885 is expressed in a variety of tissues and cells, including brain, heart, and pancreatic cancer.

Several studies have suggested that LINC02885 may have important roles in the development and progression of cancer. For example, LINC02885 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, several studies have shown that LINC02885 is involved in the regulation of key cellular processes, including cell growth, apoptosis, and inflammation.

In addition to its potential role in cancer, LINC02885 has also been suggested as a potential drug target. Several studies have shown that LINC02885 can interact with a variety of drug targets, including NF-kappa, NF-kappa-B, and SMAD. Additionally, several studies have shown that LINC02885 can modulate the expression of key drug targets, including inhibiting the activity of the NF-kappa pathway.

Furthermore, LINC02885 has also been shown to be involved in the regulation of cellular signaling pathways that are important for both cancer and non-cancer cell growth. For example, LINC02885 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is important for cell survival and proliferation.

In conclusion, LINC02885 is a unique and promising lncRNA that has been identified as a potential drug target and biomarker for several diseases. Its unique 5'-end and 3'-end features, as well as its involvement in key cellular processes and its interaction with drug targets, make it an attractive target for further study. Further research is needed to determine the full extent of LINC02885's potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2885

The "LINC02885 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02885 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets